Results 141 to 150 of about 920 (164)

Values of Cobas HPV RealTime primary screening test and CINtec PLUS cytology test in detecting women at greatest risk for development of CIN 2+ lesions

2017
HPV testing, in women more than 30 years of age, is the most powerful tool in cervical cancer screening due to its high sensitivity for detecting high grade lesions. CINtec plus cytology is very successful in detecting high grade lesions in HPV positive/cytology negative, borderline or low grade findings.
Kaliterna, Vanja, Vrdoljak-Mozetič, Danijela   +1 more
openaire  

Immunotherapies for hepatocellular carcinoma

Nature Reviews Clinical Oncology, 2021
, Florian Castet, Mala K Maini
exaly  

Comparison of HPV Testing Positive with CINtec PLUS Immunocytochemistry and Anal Cytology in Modified-LBC Preparations

Journal of the American Society of Cytopathology, 2015
Natcha Patarapadungkit, Chamsai Pientong, Tipaya Ekalasananan, Emorn Pasatung, Supinda Koonmee, Pornrith Pisuttimarn, Prinyaporn Khonhan, Piroon Mootsikapun   +7 more
openaire   +1 more source

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Nature Medicine, 2022
, Ewa Kalinka-Warzocha, Ruben G W Quek
exaly  

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nature Medicine, 2021
Ken Kato, Yoshito Komatsu, Satoshi Yuki
exaly  

Assessment of Feasibility of Integrating CINtec® PLUS Testing

Journal of the American Society of Cytopathology
Julian Tan, Yvonne Agyapong, Amrita Upadhyay, Patrick Bladek, Erin Tank, Robert Cabay, Odile David   +6 more
openaire   +1 more source

The Evaluation of Sensitivity and Specificity of the CINtec® Plus Kit for p16 and Ki-67 in HPV Related Lesions

Journal of the American Society of Cytopathology, 2014
Desiree Palafox, Desiree Carrillo, Margaret Tavares, Crystal Hernandez, Pamela Wat   +4 more
openaire   +1 more source

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Nature Medicine, 2020
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina   +2 more
exaly  

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine, 2023
Vivek Subbiah, Ulrik Lassen, J-Y Blay
exaly  

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Nature Medicine, 2020
Jianjun Gao, Omar Alhalabi, Arlene O Siefker-Radtke   +2 more
exaly